Trials / Completed
CompletedNCT04029727
Effect of the Combination of Plant Extracts (BSL_EP025) in Cardiovascular Health
Pilot Study to Evaluate the Effect of the Consumption of a Combination of Plant Extracts (BSL_EP025) on the Levels of LDL-cholesterol and Oxidized LDL-cholesterol in Healthy Volunteers
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Biosearch S.A. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The objective of the study is to evaluate the ability of a combination of plant extracts (BSL\_EP025) to reduce the levels of LDL-cholesterol and oxidized LDL-cholesterol in individuals with LDL-cholesterol levels between 100 and 190 mg/dL.
Detailed description
There is a strong relationship between serum cholesterol levels and cardiovascular diseases, especially between coronary artery disease and LDL-cholesterol (LDL). LDL is the lipoprotein responsible for delivering cholesterol to cells. However, in recent years, special attention has been given to modified LDL, especially oxidized LDL, since it plays a very important role in the initiation and progression of the atheroma plaque. There are environmental and genetic factors that can influence the type and levels of blood lipoproteins. Among the modulable factors (environmental) it has been observed that some phytochemical compounds found in several plant extracts may reduce cardiovascular risk, due to their antioxidant and anti-inflammatory properties. The objective of the present study is to evaluate the possible effect of the intake of a combination of plant extracts (BSL\_EP025) on the levels of LDL-cholesterol and oxidized LDL-cholesterol in healthy individuals with LDL-cholesterol levels between 100 and 190 mg/dL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Combination of Plant Extracts (BSL_EP025) | Each participant will consume 2 capsules daily at lunch for 8 weeks. |
| DIETARY_SUPPLEMENT | Placebo | Each participant will consume 2 capsules daily at lunch for 8 weeks. |
Timeline
- Start date
- 2019-05-24
- Primary completion
- 2019-07-31
- Completion
- 2019-07-31
- First posted
- 2019-07-23
- Last updated
- 2019-11-15
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT04029727. Inclusion in this directory is not an endorsement.